Assuring Adequate Treatment for Persons Diagnosed With Gonorrhea in New York State.
Anti-Bacterial Agents
/ pharmacology
Azithromycin
/ therapeutic use
Ceftriaxone
/ therapeutic use
Drug Resistance, Microbial
Gonorrhea
/ diagnosis
Guideline Adherence
/ statistics & numerical data
Humans
Microbial Sensitivity Tests
Neisseria gonorrhoeae
/ drug effects
New York City
/ epidemiology
Population Surveillance
Sentinel Surveillance
United States
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
entrez:
12
10
2020
pubmed:
13
10
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
From November 2014 to May 2016, 57 local health departments in New York State (NYS) excluding New York City were offered a performance incentive (PI) to promote adherence to federally recommended treatment guidelines for gonorrhea. The rationale of the PI was to delay antibiotic resistance and disrupt transmission through attaining a high percentage of treatment adherence. Surveillance data from the NYS Communicable Disease Electronic Surveillance System were used for analysis. We evaluated adherence per Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines for persons 12 years and older reported with uncomplicated gonorrhea during 4 time frames: Pre-PI, PI One, PI Two, and Post-PI. We measured adherence per the Centers for Disease Control and Prevention sexually transmitted disease treatment guidelines during each respective time frame and conducted χ tests to test for the association between treatment adequacy and time frame. During the Pre-PI, treatment was adequate in 82.0% of persons diagnosed with gonorrhea. After program implementation, treatment adequacy increased significantly (92.1% of diagnosed persons during PI One, 90.4% during PI Two, and 90.5% during the Post-PI; P ≤ 0.0001). The most common reason for inadequate or missing treatment was patient lost to follow-up. Public health intervention by the NYS Department of Health improved local health department adherence to federally recommended gonorrhea treatment guidelines, and improvements were maintained after the completion of the PI.
Sections du résumé
BACKGROUND
From November 2014 to May 2016, 57 local health departments in New York State (NYS) excluding New York City were offered a performance incentive (PI) to promote adherence to federally recommended treatment guidelines for gonorrhea. The rationale of the PI was to delay antibiotic resistance and disrupt transmission through attaining a high percentage of treatment adherence.
METHODS
Surveillance data from the NYS Communicable Disease Electronic Surveillance System were used for analysis. We evaluated adherence per Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines for persons 12 years and older reported with uncomplicated gonorrhea during 4 time frames: Pre-PI, PI One, PI Two, and Post-PI. We measured adherence per the Centers for Disease Control and Prevention sexually transmitted disease treatment guidelines during each respective time frame and conducted χ tests to test for the association between treatment adequacy and time frame.
RESULTS
During the Pre-PI, treatment was adequate in 82.0% of persons diagnosed with gonorrhea. After program implementation, treatment adequacy increased significantly (92.1% of diagnosed persons during PI One, 90.4% during PI Two, and 90.5% during the Post-PI; P ≤ 0.0001). The most common reason for inadequate or missing treatment was patient lost to follow-up.
CONCLUSIONS
Public health intervention by the NYS Department of Health improved local health department adherence to federally recommended gonorrhea treatment guidelines, and improvements were maintained after the completion of the PI.
Identifiants
pubmed: 33045162
doi: 10.1097/OLQ.0000000000001241
pii: 00007435-202011000-00004
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ceftriaxone
75J73V1629
Azithromycin
83905-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
733-738Références
Braxton J, Davis DW, Emerson B, et al. Centers for Disease Control and Prevention sexually transmitted disease surveillance 2017. HIV AIDS Surveill Rep 2018.
Wi T, Lahra M, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med 2017; 14:e1002344.
Deguchi T, Nakane K, Yasuda M, et al. Emergence and spread of drug resistant Neisseria gonorrhoeae. J Urol 2010; 184:851–858.
Chesson HW, Kirkcaldy RD, Gift TL, et al. An illustration of the potential health and economic benefits of combating antibiotic-resistant gonorrhea. Sex Transm Dis 2018; 45:250.
Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. MMWR Recomm Rep 2006; 55:2–49.
Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010. MMWR Recomm Rep 2010; 59.
Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Recomm Rep 2012; 61:590–594.
Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64(RR-03):1–137.
Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16:19833.
Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012; 39:877–879.
Waters LJ, Boag FC, Betournay R. Efficacy of azithromycin 1 g single dose in the management of uncomplicated gonorrhoea. Int J STD AIDS 2005; 16:84.
McLean CA, Wang SA, Hoff GL, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. Sex Transm Dis 2004; 31:73–78.
Chisholm SA, Neal TJ, Alawattegama AB, et al. Emergence of high level Azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009; 64:353–358.
New York Consolidated Laws, Public Health Law, Article 6—Title 1, §602(b). The New York State Senate. 2017. Available at: https://www.nysenate.gov/legislation/laws/PBH/A6. Accessed May 31, 2020.
Town R, Kane R, Johnson P, et al. Economic incentives and physicians’ delivery of preventive care: a systematic review. Am J Prev Med 2005; 28:234–240.
Andersen LB. What determines the behaviour and performance of health professionals? Public service motivation, professional norms and/or economic incentives. Int Rev of Adm Sci 2009; 75:79–97.
Lagarde M, Blaauw D. Physicians’ responses to financial and social incentives: A medically framed real effort experiment. Soc Sci Med 2017; 179:147–159.
Weston EJ, Workowski K, Torrone E, et al. Adherence to CDC recommendations for the treatment of uncomplicated gonorrhea—STD Surveillance Network (SSuN), United States, 2016. MMWR Recomm Rep 2018; 67:473–476.
Smith MK, Shen H, Huang S, et al. Detection-based monetary incentives to improve syphilis screening uptake: results of a pilot intervention in a high transmission setting in Southern China. Sex Transm Dis 2020; 47:187–191.
Fenton KA, Steiner RJ. Program collaboration and service integration: implementation successes and challenges. Sex Transm Dis 2013; 40:675–677.